37 results  1 of 2 

1 Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
Maria Gemelli, Elena Maria Elli, Chiara Elena, Alessandra Iurlo, Tamara Intermesoli, Margherita Maffioli, Ester Pungolino, Maria Cristina Carraro, Mariella D’Adda, Francesca Lunghi, Michela Anghileri, Nicola Polverelli, Marianna Rossi, Mattia Bacciocchi, Elisa Bono, Cristina Bucelli, Francesco Passamonti, Laura Antolini, Carlo Gambacorti-Passerini
Blood Res.2020;55(3):139-145.   Published online 2020 September 30     DOI: http://dx.doi.org/10.5045/br.2020.2020130
      
2 Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Juwhan Choi, Sung Yong Lee
Immune Netw.2020;20(1):e9.  Published online 2020 February 17     DOI: http://dx.doi.org/10.4110/in.2020.20.e9
      
3 Safety Issues with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical Considerations
Soo Lim
J Korean Diabetes.2019;20(3):127-135.   Published online 2019 September 30     DOI: http://dx.doi.org/10.4093/jkd.2019.20.3.127
      
4 Immune-related Adverse Events: Overview and Management Strategies for the Use of Immune Checkpoint Inhibitors
Hei-Cheul Jeung, Se Eung Oh, Jee Hung Kim
J Rheum Dis.2019;26(4):221-234.   Published online 2019 September 30     DOI: http://dx.doi.org/10.4078/jrd.2019.26.4.221
      
5 Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy
Ye Jin Lee, Hak Tae Kim, Chong Hyun Won, Sung Eun Chang, Mi Woo Lee, Jee Ho Choi, Woo Jin Lee
J Korean Med Sci.2019;34(26):e186.  Published online 2019 June 17     DOI: http://dx.doi.org/10.3346/jkms.2019.34.e186
   
6 A Case of Aggravation of Thyroid Goiter after Treatment with PD-1 Inhibitor for Breast Cancer in Patients with Underlying Hashimoto's Thyroiditis
Hana Kim, Min Joo Kim, Young Shin Song, Sun Wook Cho
Int J Thyroidol.2018;11(2):172-175.   Published online 2018 November 30     DOI: http://dx.doi.org/10.11106/ijt.2018.11.2.172
      
7 Adverse Events of Tyrosine Kinase Inhibitors in Patients with Advanced Thyroid Cancer
Min Joo Kim, Young Joo Park
Int J Thyroidol.2018;11(2):61-70.   Published online 2018 November 30     DOI: http://dx.doi.org/10.11106/ijt.2018.11.2.61
      
8 Management of Severe Fatigue Induced by Tyrosine Kinase Inhibitor in Radioiodine Refractory Thyroid Cancer
Byeong-Cheol Ahn
Int J Thyroidol.2018;11(2):75-77.   Published online 2018 November 30     DOI: http://dx.doi.org/10.11106/ijt.2018.11.2.75
      
9 A Case Report of Severe Hypocalcemia and Hypothyroidism after Tyrosine Kinase Inhibitor Treatment
Eun Kyung Lee, Young Ki Lee, Yul Hwangbo, You Jin Lee
Int J Thyroidol.2018;11(2):88-91.   Published online 2018 November 30     DOI: http://dx.doi.org/10.11106/ijt.2018.11.2.88
      
10 Post lumbar puncture headache: Case report of a serious adverse event in first-in-human study
Wonsuk Shin, Min-Kyoung Kim, Jinkwon Kim, Min-Hee Woo, Doo-Yeon Cho, Kyoung Soo Lim
Transl Clin Pharmacol.2017;25(4):162-165.   Published online 2017 December 20     DOI: http://dx.doi.org/10.12793/tcp.2017.25.4.162
      
11 Risk Factors for the Adverse Events after Conversion from Twice-Daily to Once-Daily Tacrolimus in Stable Liver Transplantation Patients
Suk-Won Suh, Kwang-Woong Lee, Jaehong Jeong, Hyeyoung Kim, Nam-Joon Yi, Kyung-Suk Suh
J Korean Med Sci.2016;31(11):1711-1716.   Published online 2016 September 6     DOI: http://dx.doi.org/10.3346/jkms.2016.31.11.1711
      
12 Recent Updates on the Management of Medullary Thyroid Carcinoma
Bo Hyun Kim, In Joo Kim
Endocrinol Metab.2016;31(3):392-399.   Published online 2016 August 26     DOI: http://dx.doi.org/10.3803/EnM.2016.31.3.392
      
13 Signal Detection of Adverse Drug Reaction of Amoxicillin Using the Korea Adverse Event Reporting System Database
Mick Soukavong, Jungmee Kim, Kyounghoon Park, Bo Ram Yang, Joongyub Lee, Xue-Mei Jin, Byung-Joo Park
J Korean Med Sci.2016;31(9):1355-1361.   Published online 2016 June 13     DOI: http://dx.doi.org/10.3346/jkms.2016.31.9.1355
      
14 Clinical Features of Post-Vaccination Guillain-Barré Syndrome (GBS) in Korea
Yong-Shik Park, Keon-Joo Lee, Seung Woo Kim, Kyung Min Kim, Bum Chun Suh
J Korean Med Sci.2017;32(7):1154-1159.   Published online 2016 May 19     DOI: http://dx.doi.org/10.3346/jkms.2017.32.7.1154
      
15 Alendronate use and Changes in Bone Mineral Density
Sang Hyup Yoon, Shin Yoon Kim
J Korean Hip Soc.2009;21(1):22-28.   Published online 2016 May 3     DOI: http://dx.doi.org/10.5371/jkhs.2009.21.1.22
      
16 Healthcare Professionals Involved in Medical Errors and Support Systems for Them: A Literature Review
Haena Jang, Nam-Ju Lee
Perspect Nurs Sci.2016;13(1):1-9.   Published online 2016 April 29     DOI: http://dx.doi.org/10.16952/pns.2016.13.1.1
      
17 Ultrarush schedule of subcutaneous immunotherapy with modified allergen extracts is safe in paediatric age
Mário Morais-Almeida, Cristina Arêde, Graça Sampaio, Luis Miguel Borrego
Asia Pac Allergy.2016;6(1):35-42.   Published online 2016 January 27     DOI: http://dx.doi.org/10.5415/apallergy.2016.6.1.35
      
18 Serious adverse events during clinical trial for pharmacokinetic interaction between telmisartan and chlorthalidone in healthy Korean subjects: A case report
Sook Jin Seong, Young-Ran Yoon, Mi-sun Lim
Transl Clin Pharmacol.2015;23(2):46-48.   Published online 2015 December 8     DOI: http://dx.doi.org/10.12793/tcp.2015.23.2.46
      
19 Pediatric Medication Error Reports in Korea Adverse Event Reporting System Database, 1989-2012: Comparing with Adult Reports
Yeonju Woo, Hyung Eun Kim, Sooyoun Chung, Byung Joo Park
J Korean Med Sci.2015;30(4):371-377.   Published online 2015 March 19     DOI: http://dx.doi.org/10.3346/jkms.2015.30.4.371
      
20 Repeated Administration of Newly Synthesized Aceclofenac Sustained Release Form Causes Agranulocytosis: Case Report of an Unforeseen Adverse Event during the Phase 1 Trial
Hui Jin, Renhua Zheng, BoHyung Kim, Sung-Vin Yim
Transl Clin Pharmacol.2014;22(1):11-12.   Published online 2014 June 30     DOI: http://dx.doi.org/10.12793/tcp.2014.22.1.11
      

 1 of 2